Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Apple Turns 50: From Garage Startup to AI Crossroads 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
Britain Courts Anthropic Amid US Defense Department Dispute 
NEW YORK, Jan. 30, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of New Jersey on behalf of investors who purchased PixarBio Corporation (OTCMKTS:PXRB) securities (1) pursuant and/or traceable to PixarBio’s private placement that closed on October 30, 2016; and/or (2) publicly traded on the open market from October 31, 2016 through January 20, 2017.
Click here to learn about the case: http://www.wongesq.com/pslra/pixarbio-corporation. There is no cost or obligation to you.
According to the complaint, PixarBio made false and/or misleading statements and/or failed to disclose that: (1) the market for PixarBio’s securities exhibited manipulative or deceptive activities; (2) certain assertions in press releases, third party promotional materials, and PixarBio’s Form S-1 lacked accuracy; and (3) as a result, the Company’s public statements were materially false and misleading.
If you suffered a loss in PixarBio you have until March 27, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/pixarbio-corporation.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
